Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 2/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9567700 | 1.00 | HSD17B10 (0.47) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| SCHEMBL12047940 | 1.00 | HSD17B10 (0.47) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| SCHEMBL5498935 | 1.00 | HSD17B10 (0.47) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| SCHEMBL2150205 | 1.00 | HSD17B10 (0.47) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| SCHEMBL2150208 | 1.00 | HSD17B10 (0.47) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL10671526 | 0.99 | HSD17B10 (0.46) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL9481622 | 0.99 | HSD17B10 (0.46) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL3912152 | 0.99 | HSD17B10 (0.46) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL5147558 | 0.99 | HSD17B10 (0.46) | HSD17B10KDM4ETDP1TSHRPTGS1 | |
| Hydrochloric Acid SCHEMBL5147561 | 0.99 | HSD17B10 (0.46) | HSD17B10KDM4ETDP1TSHRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347362-B1 | PROCESS FOR PREPARING CEFTOLOZANE FROM 7-AMINOCEPHALOSPORANIC ACID (7-ACA) | SANDOZ AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-9677112-B2 | β-lactamase substrates and methods of their use for the diagnosis of tuberculosis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-06-13 | — | — | US | disclosed |
| US-9677112-B2 | β-lactamase substrates and methods of their use for the diagnosis of tuberculosis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2763539-B1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-02-08 | — | — | EP | disclosed |
| US-9340556-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-06-18 | — | — | US | disclosed |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-7427680-B2 | Fluorogenic substrates for BETA-lactamase gene expression | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-0346465-B1 | 1-CARBOXY-1-VYNILOXYIMINOAMINOTHIAZOLE CEPHALOSPORING DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-11 | — | — | EP | disclosed |
| EP-0550775-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-07-14 | — | — | EP | disclosed |
| US-5225406-A | Antibiotics | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| US-5194432-A | Drugs for treatment of infectious diseases; microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0492277-A2 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-07-01 | — | — | EP | disclosed |
| US-5084453-A | Antibiotics, bactericides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-28 | — | — | US | disclosed |
| US-5061794-A | Effective against pseudomonads | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
| US-4960766-A | SUBSTITUTED 2-PYRAZOLIOMETHYL GROUP AND A 7-(AMINOTHIAZOLYL) (ALKOXYIMINO)-ACETAMIDO GROUP CEPHALOSPORIN DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-02 | — | — | US | disclosed |
| EP-0346465-A1 | 1-CARBOXY-1-VYNILOXYIMINOAMINOTHIAZOLE CEPHALOSPORING DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-12-20 | — | — | EP | disclosed |
| EP-0241901-A2 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | PGLS, ENGASE, BPHL | HSD17B10 312/4885KDM4E 3809/4885TDP1 2256/4885 |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, PEPD, ABCB11 | HSD17B10 2272/4885KDM4E 3556/4885TDP1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.